Broker's call: Caplin Point (Accumulate)
Hem SecuritiesCaplin Point (Accumulate)Target: 896CMP: 831.55Total Revenue stood at 312.02 crore for Q2-FY22, registering a growth of 15.6 per cent29-12-2021
29-12-2021
CAPLIN POINT LABORATORIES LTD. - 524742 - Closure of Trading Window
Closure of Trading Window28-12-2021
CAPLIN POINT LABORATORIES LTD. - 524742 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate07-12-2021
CAPLIN POINT LABORATORIES LTD. - 524742 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Loss of Share Certificate of Mr. Ganesan R20-11-2021
Buy Caplin Point Laboratories; target of Rs 1080: ICICI Direct
ICICI Direct is bullish on Caplin Point Laboratories has recommended buy rating on the stock with a target price of Rs 1080 in its research report dated November 03, 2021.05-11-2021
Caplin Point Laboratories Ltd - 524742 - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
Allotment of Equity Shares on Exercise of ESOPs03-11-2021
Earnings Call for Q2FY22 of Caplin Point Laboratories
Conference Call with Caplin Point Laboratories Management and Analysts on Q2FY22 Performance and Outlook. Listen to the full earnings transcript.02-11-2021
Q2FY22 Quarterly Result Announced for Caplin Point Laboratories Ltd.
Key Highlights (Consolidated): Cash Reserves at Rs. 562 Cr Revenue for the H1FY22 grew by 20% YoY to Rs. 622cr. Gross margin for half year expanded by 176 bps YoY to 56.7% whereas for the quarter the gross margins expanded by 345bps YoY to 58.6% H1FY22 PAT was at Rs. 148cr. up 26.4% YoY Cash and Cash Surplus at Rs. 562cr. as at end of September 2021 - increase of Rs 92 Cr over March 2021 balance. Free cash flow stood at Rs. 103 Cr as at Sep 21 Receivable days stable at 93 days as on Sep 21 Q2 FY22 Revenue at Rs. 312 Cr, up 15.6% YoY, as compared to Rs. 270 Cr in Q2 FY21 H1FY22 Revenue up 20% YoY, PAT up 26% YoY Gross Margins improved to 58.6% in Q2FY22 from 55.1% in Q2FY21 and 54.7% in Q1FY22 PAT increased by 26.4% to Rs. 148 Cr in H1FY22 against Rs. 117 Cr in H1FY21 PAT for the quarter was at Rs. 77cr. up 22% as compared to Rs. 63cr in Q2FY21 Cash flow From Operations at Rs 131cr. in H1FY22 as against Rs 266 Cr for the whole year FY21 Basic EPS grew by 31% to Rs. 19.28 in H1FY22 against Rs. 14.73 in H1FY21 (not Annualized) With depreciation of INR against USD, exchange gain in H1FY22 is Rs. 5.33cr and for Q2 FY22 is Rs. 1.75 Cr as against exchange loss of Rs. (2.01) Cr in H1FY21 and Rs. (3.77) Cr in Q2 FY21 With continued focus on Cash Flow, Receivables sustained at 93 days despite growth in sales Inventory stood at Rs. 237cr (including transit inventory of Rs.126 Cr) in Sep 21 as against Rs. 193 Cr in June 21. Geographical breakup of sales: LATAM & ROW - 90%, US – 10% Result PDF02-11-2021
Caplin Point Laboratories Ltd - 524742 - Unaudited Standalone And Consolidated Financial Results For The Quarter And Six Months Ended September 30, 2021.
Unaudited Standalone and Consolidated Financial Results for the quarter and six months ended September 30, 2021.02-11-2021